ATE93721T1 - Verwendung von fluoxetin zur behandlung des diabetes. - Google Patents

Verwendung von fluoxetin zur behandlung des diabetes.

Info

Publication number
ATE93721T1
ATE93721T1 AT88303930T AT88303930T ATE93721T1 AT E93721 T1 ATE93721 T1 AT E93721T1 AT 88303930 T AT88303930 T AT 88303930T AT 88303930 T AT88303930 T AT 88303930T AT E93721 T1 ATE93721 T1 AT E93721T1
Authority
AT
Austria
Prior art keywords
fluoxetin
treat diabetes
diabetes
treat
fluoxetine
Prior art date
Application number
AT88303930T
Other languages
English (en)
Inventor
David Taiwai Wong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE93721T1 publication Critical patent/ATE93721T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
AT88303930T 1987-05-04 1988-04-29 Verwendung von fluoxetin zur behandlung des diabetes. ATE93721T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4550987A 1987-05-04 1987-05-04
EP88303930A EP0294028B1 (de) 1987-05-04 1988-04-29 Verwendung von Fluoxetin zur Behandlung des Diabetes

Publications (1)

Publication Number Publication Date
ATE93721T1 true ATE93721T1 (de) 1993-09-15

Family

ID=21938301

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88303930T ATE93721T1 (de) 1987-05-04 1988-04-29 Verwendung von fluoxetin zur behandlung des diabetes.

Country Status (11)

Country Link
EP (1) EP0294028B1 (de)
JP (1) JP2721507B2 (de)
KR (1) KR880013555A (de)
AT (1) ATE93721T1 (de)
AU (1) AU596296B2 (de)
DE (1) DE3883606T2 (de)
DK (1) DK238588A (de)
ES (1) ES2058272T3 (de)
HK (1) HK19595A (de)
PH (1) PH23901A (de)
ZA (1) ZA883115B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449562A3 (en) * 1990-03-29 1992-03-18 Eli Lilly And Company Use of r-fluoxetine as selective serotonin ic-receptor ligands
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
US7034059B2 (en) 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
CN101588795A (zh) 2006-11-09 2009-11-25 奥雷西根治疗公司 包含中间快速溶解层的分层药物制剂
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
EP3659604A1 (de) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Verfahren zur bereitstellung einer gewichtsverlusttherapie für patienten mit schweren depressionen
HUE049859T2 (hu) 2012-06-06 2020-10-28 Nalpropion Pharmaceuticals Llc Készítmény magas kardiovaszkuláris kockázatnak kitett páciensekben túlsúly és elhízás kezelésére szolgáló eljárásban történõ alkalmazásra
WO2014021801A1 (en) 2012-07-31 2014-02-06 Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret A.S. Use of fluoxetine in animals
EP2879517A1 (de) 2012-07-31 2015-06-10 Sanovel Hayvan Sagligi Ürünleri Sanayi ve Ticaret A.S. Verwendung von fluoxetin zur steigerung der fleisch- und milchproduktion
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4590213A (en) * 1983-04-08 1986-05-20 Eli Lilly And Company Anti-anxiety method
CA1267092A (en) * 1985-02-25 1990-03-27 Martin D. Hynes Analgesic composition containing codeine

Also Published As

Publication number Publication date
JPS63284126A (ja) 1988-11-21
ZA883115B (en) 1990-01-31
DE3883606D1 (de) 1993-10-07
AU596296B2 (en) 1990-04-26
DK238588A (da) 1988-11-05
JP2721507B2 (ja) 1998-03-04
AU1553388A (en) 1988-11-10
ES2058272T3 (es) 1994-11-01
EP0294028A3 (en) 1990-05-02
PH23901A (en) 1989-12-18
DK238588D0 (da) 1988-05-03
KR880013555A (ko) 1988-12-21
EP0294028A2 (de) 1988-12-07
DE3883606T2 (de) 1994-01-20
EP0294028B1 (de) 1993-09-01
HK19595A (en) 1995-02-17

Similar Documents

Publication Publication Date Title
ATE93721T1 (de) Verwendung von fluoxetin zur behandlung des diabetes.
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE3584013D1 (de) Zubereitung zur behandlung von psoriasis.
DE3878627D1 (de) Zusammensetzung zur oberflaechenbehandlung von kautschuk.
DE3772429D1 (de) Pharmazeutisches praeparat zur behandlung von peridontalkrankheiten.
DE3884895D1 (de) Verwendung von Bezafibrat zur Behandlung von Diabetes.
DE69013999D1 (de) Siliconkautschukzusammensetzung zur Behandlung von Faserstrukturen.
DE3869590D1 (de) Mischung zur behandlung von hypercholesterolemie.
DE69325029D1 (de) Verwendung der il-10 zur verhinderung des insulin-abhängigen diabetes mellitus
ATE106736T1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
DE3680507D1 (de) Verwendung von oxirancarbonsaeuren zur behandlung der hyperlipaemie.
DE3875016D1 (de) Therapeutikum zur behandlung von aids.
DE3781667D1 (de) Verwendung von 24,25-dihydroxycholecalciferol zur verhuetung des knochenalterns.
ATE59780T1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
PT80152A (de) Methode zur behandlung des glaukoms vok
DE3787954D1 (de) Verwendung von 5-(Subst. Phenyl)- Oxazolidinonderivaten zur Behandlung von Depressionen.
DE3686688D1 (de) Verwendung von sulfanilamido quinoxalinen zur behandlung von neoplastischen krankheiten.
DE3684825D1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
DE3675720D1 (de) Behandlung von material aus lignocellulose.
DE3583337D1 (de) Zusammensetzung zur behandlung von haemorroiden.
DE3688742D1 (de) 2,2-diphenoxy-n,n-dimethylaminoaethan zur verbesserung der sauerstoffversorgung des gehirns.
DE69232918D1 (de) Verwendung von Carbachol zur Behandlung verringerter willkürlicher Mobilität
ATE81001T1 (de) Verwendung von ketonderivaten zur behandlung von bewusstseinsstoerungen.
ATE64683T1 (de) Zusammensetzung zur behandlung von haemorroiden.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee